Taipei, Taiwan, June 13, 2017
General Life Biotechnology Co., Ltd., an affiliate of Compal Group (TWSE:2324), has signed a contract with Hukui Biotechnology Corporation. General Life Biotechnology Co., Ltd. will provide the key components and technical support, and Hukui Technology, the Chongqing-based subsidiary of Hukui Biotechnology Corporation is then responsible to apply for the license and manufacture equipment and supplies for blood sugar, cholesterol, and uric acid to sell in China.
In recent years, a policy, “Made in China 2025”, has been implemented by China to improve its manufacturing level, medical products industry in particular. According to the Chinese government’s plan, by 2025, 70% of the medical equipment used by domestic public hospitals is aimed to be made in China, which will have a huge impact on imported medical equipment. In addition, from May 2015, the Chinese government started to charge a registration fee on the imported medical equipment and also makes the application on the extension of licenses much more difficult. Understanding this difficult situation, honorary Vice Chairman of UMC (NYSE:UMC, TWSE:2303), also the Chairman of Hukui Biotechnology Corporation, John Hsuan and Hukui Biotechnology Corporation together, invested over NT$50 million to build a factory with an area of 4,200 square meter, which meets the regulations of manufacturing medical instruments in Chongqing. Chairman John Hsuan said that, this would not only save time for applying for licenses with China Food and Drug Administration (CFDA), also save the cost of factory construction and a high registration fee. For the foreign medical equipment, this will be a quick access to enter into the Chinese market
Founded in 1999, General Life Biotechnology Co., Ltd. is an affiliate of Compal Group and has its own brand called “BeneCheck”. The company’s vision is to become a leading medical equipment manufacturer that offers comprehensive services. Based on its self-testing equipment, the company aims to build the preventive medicine at a low cost and improve health care system to every household. The R&D team focuses on two fields of development: screen-printed electrode (SPE) and electrochemical detection. With its advanced technologies, the company can develop areas in biochemistry, immunology, and molecular biology and to apply these technologies to clinical and home testing. In addition to its own brand, the company also focuses on OEM/ODM by taking advantage of its advanced R&D technologies, rich experience in product development, and experts in electronic, biochemical, and software R&D teams, institutional engineers, design packaging staff, and patent certification. As of today, the company has obtained a variety of certifications, including GMP, TFDA, CFDA, KFDA, CE Mark, and FDA and has its products sold in over 80 countries.
CEO of Hukui Biotechnology Corporation, Michael Kuo said that, Hukui Biotechnology Corporation has invested over NT$100 million in building a turnkey service in China for past three years. As a creative business model, the turnkey service will not only accelerate in obtaining license, followed by production, but also help in selling the products to different channels that have good relationships with Hukui Biotechnology Corporation. Hukui Biotechnology Corporation has created this successful model and will continue to promote this turnkey service to countries worldwide.
Company Profile of Hukui Biotechnology Corporation:
Led by honorary Vice Chairman of UMC (NYSE:UMC, TWSE:2303), also Chairman John Hsuan, Hukui Biotechnology Corporation positions itself as the industrial platform for the biotechnology and big health industry. Hukui Biotechnology Corporation provides the turnkey services for selected outstanding biotechnology and medical device companies. Three main services provided by Hukui Biotechnology Corporation include: (1) accelerate in obtaining licenses in China; (2) OEM/ODM production services in factory of Hukui Technology meeting the specifications of the GMP and ISO13485 in China; and (3) strategic cooperation with the largest local medical channel in selling products. Through the turnkey services, outstanding biomedical companies worldwide can obtain licenses faster, invest at the lower cost, and more efficiently control local marketing channels, allowing them to have stronger competitive advantages in the market.